MAPT and Cognitive impairment: More recently, the AD field has shifted its focus toward molecular targets (e.g., TREM2 [1] and CD33 [2]) aimed at preventing β-amyloid and tau pathologies in presymptomatic patients before cognitive impairment occurs or in patients with mild cognitive impairment before irreversible neuronal damage occurs.